Skip to content

Welcome to Discover Pharma! Today is : October 11, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Tris Pharma

  • Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Tris Pharma partners with Calm Health and ADHD Central to support patients

    Tris Pharma has announced partnerships with Calm Health and ADHD [...]

    August 14, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants orphan drug designation to Tris Pharma’s TRN-257 for idiopathic hypersomnia

    FDA has granted orphan drug designation to Tris Pharma’s investigational [...]

    June 11, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Novadip secures €10.4M to advance pivotal Phase 3 trial
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Telix to acquire ITM in $1.65BN radiopharmaceutical deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top